Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.

@article{Dransfield2013OncedailyIF,
  title={Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.},
  author={Mark Thomas Dransfield and Jean Bourbeau and Paul W. Jones and Nicola Alexander Hanania and Donald A. Mahler and J\orgen Vestbo and Andrew Wachtel and Fernando J Martinez and Frank Barnhart and Lisa Sanford and Sally Lettis and Courtney C Crim and Peter M. A. Calverley},
  journal={The Lancet. Respiratory medicine},
  year={2013},
  volume={1 3},
  pages={210-23}
}
BACKGROUND Whether the combination of a once-daily inhaled corticosteroid with a once-daily longacting β(2) agonist is more protective than a once-daily longacting β(2) agonist alone against exacerbations of chronic obstructive pulmonary disease (COPD) is unknown. We hypothesised that fluticasone furoate and vilanterol would prevent more exacerbations than would vilanterol alone. METHODS We did two replicate double-blind parallel-group 1 year trials. Both studies began on Sept 25, 2009. Study… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 4 times over the past 90 days. VIEW TWEETS
108 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 108 extracted citations

Similar Papers

Loading similar papers…